A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 10, 2013

Primary Completion Date

October 9, 2019

Study Completion Date

October 9, 2019

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Tocilizumab

Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.

Trial Locations (19)

1270

Hospital Gral de Niños Pedro Elizalde, Buenos Aires

5519

Hospital Dr. Humberto Notti, Mendoza

13353

Charité Campus; Virchow Klinikum Berlin, Berlin

21100

Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel, Mexicali

28034

Hospital Ramon y Cajal ; Servicio de Reumatologia, Madrid

28046

Hospital de La Paz; Unidad de Reumatologia Pediatrica, Madrid

35128

Univ. Di Padova - Dip. Di Pediatria - Unita' Reumatol. Pediatrica, Padua

53757

Asklepios Klinik; Zentrum für Allgemeine Pädiatrie und Neonatologie, Sankt Augustin

90027

Children's Hospital Los Angeles; Division of Rheumatoogy, Los Angeles

119991

SI Sceintific children health center RAMS, Moscow

194100

Saint-Petersburg State; Pediatrics Medical Academy, Saint Petersburg

3109601

Rambam Medicl Center, Ruth Children Hospital, Haifa

4428164

Meir Medical center, Pediatrics, Kfar Saba

4920235

Schneider Children's Medical Center of Israel, Petah Tikva

45229-3039

Cincinnati Children'S Hospital Medical Center; Division of Rheumatology, Cincinnati

T3B 6A8

Alberta Children'S Hospital, Calgary

00165

Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina, Rome

08950

Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica, Barcelona

L12 2AP

Royal Liverpool Childrens Hospital; Rheumatology, Liverpool

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01734382 - A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) | Biotech Hunter | Biotech Hunter